A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.

Abstract:

BACKGROUND AND PURPOSE:Vandetanib is a promising anticancer targeted agent for treating advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer, malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic medullary thyroid cancer. However, diarrhea is a frequently reported adverse event. The incidence of vandetanib-associated diarrhea varies extensively in different study populations and has not been carefully estimated. This systematic review and meta-analysis of clinical trials aims to figure out the overall risks of all-grade and high-grade diarrhea during vandetanib treatment and get a better understanding of its prediction and management. MATERIALS AND METHODS:A comprehensive search was performed in EMBASE, PubMed, and Cochrane Library for clinical trials studying vandetanib and diarrhea prior to April 2015. Eligible articles were selected according to the inclusion criteria. Data were extracted to calculate the summary incidence of all-grade and high-grade diarrhea caused by vandetanib treatment. RESULTS:Thirteen clinical trials that involved 3,264 patients were included in this meta-analysis. The overall incidences of all-grade and high-grade diarrhea caused by vandetanib treatment were 52.1% (95% confidence interval [CI], 48.3%-55.8%) and 5.6% (95% CI, 4.4%-76.7%), respectively. The risk ratios of the all-grade and high-grade diarrhea for vandetanib arm versus control arm were 1.932 (95% CI, 1.746-2.138; P<0.001) and 3.190 (95% CI, 2.061-4.938; P<0.001), respectively. Studies with small-cell lung cancer demonstrated the highest incidence of all-grade diarrhea (78.85%) and high-grade diarrhea (17.31%), whereas the lowest incidences of all-grade (42.11%) and high-grade (2.67%) diarrhea are seen in patients with hepatocellular carcinoma and non-small-cell lung cancer, respectively. CONCLUSION:Our findings demonstrate that the administration of vandetanib leads to a significantly increased risk of diarrhea, which varies in different carcinoma patients. Early recognition and timely management may be key factors to avoid dose reduction, drug interruption, and drug discontinuation, which is significant to maximize the treatment benefits.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Huo Z,Yu S,Hong S,Cao X,Xiu L,Liao Z,Li Y,Xiao H

doi

10.2147/OTT.S96830

subject

Has Abstract

pub_date

2016-06-20 00:00:00

pages

3621-31

issn

1178-6930

pii

ott-9-3621

journal_volume

9

pub_type

杂志文章
  • Differential expression of two activating transcription factor 5 isoforms in papillary thyroid carcinoma.

    abstract:BACKGROUND:Activating transcription factor 5 (ATF5) is a member of the activating transcription/cAMP response element-binding protein family of basic leucine zipper proteins that plays an important role in cell survival, differentiation, proliferation, and apoptosis. The ATF5 gene generates two transcripts: ATF5 isofor...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S113194

    authors: Vicari L,La Rosa C,Forte S,Calabrese G,Colarossi C,Aiello E,Salluzzo S,Memeo L

    更新日期:2016-10-11 00:00:00

  • TLR9 signaling activation at different stages in colorectal cancer and NF-kappaB expression.

    abstract:Background:The relationship of inflammation and tumor is becoming more and more important in the study on the pathogenesis of colorectal cancer. The role of TLR9-mediated immune inflammation reaction in the process is not currently clear. The purpose of the study was to discuss the correlation of TLR9 signal activation...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S174274

    authors: Gao C,Qiao T,Zhang B,Yuan S,Zhuang X,Luo Y

    更新日期:2018-09-18 00:00:00

  • Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.

    abstract:PURPOSE:Programmed death-ligand 1 (PD-L1) is found to be overexpressed in non-small cell lung cancer. The present study intended to evaluate the status of PD-L1 expression in patients with resection and recurrent lung adenocarcinoma. PATIENTS AND METHODS:Matched resection and recurrent tumor samples were harvested fro...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S127498

    authors: Chen J,Li H,Pang R,Huang J

    更新日期:2017-04-06 00:00:00

  • p53 inhibits the expression of p125 and the methylation of POLD1 gene promoter by downregulating the Sp1-induced DNMT1 activities in breast cancer.

    abstract::p125 is one of four subunits of human DNA polymerases - DNA Pol δ as well as one of p53 target protein encoded by POLD1. However, the function and significance of p125 and the role that p53 plays in regulating p125 expression are not fully understood in breast cancer. Tissue sections of human breast cancer obtained fr...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S98713

    authors: Zhang L,Yang W,Zhu X,Wei C

    更新日期:2016-03-10 00:00:00

  • Long-term complete remission in a patient with intravascular large B-cell lymphoma with central nervous system involvement.

    abstract::This report describes a patient with intravascular large B-cell lymphoma (IVLBCL) with central nervous system involvement at the time of diagnosis who achieved complete remission for over 5 years in response to therapy. The patient, a 71 year-old woman, was previously healthy with the exception of taking verapamil for...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S72596

    authors: Sawada T,Omuro Y,Kobayashi T,Hishima T,Koizumi F,Kanemasa Y,Shimoyama T,Sasaki E,Maeda Y

    更新日期:2014-11-18 00:00:00

  • Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating m6A Methylation on TCF1.

    abstract:Objective:This study aims to uncover the progression of thyroid carcinoma influenced by the m6A methyltransferase METTL3 through regulating m6A methylation on TCF1 mRNA and the activated Wnt pathway. Methods:Thyroid carcinoma tissues and paracancerous ones were collected for detecting levels of METTL3 and TCF1. Potent...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S234751

    authors: Wang K,Jiang L,Zhang Y,Chen C

    更新日期:2020-02-21 00:00:00

  • Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors.

    abstract::Neuroendocrine tumors are a rare and heterogeneous group of tumors with a variety of primary origins and variable aggressiveness. Platinum-based chemotherapy has been the cornerstone of treatment for the poorly differentiated tumors. However, well-differentiated neuroendocrine tumors are quite chemoresistant and thera...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S72155

    authors: Kotteas EA,Syrigos KN,Saif MW

    更新日期:2016-02-09 00:00:00

  • MiR-200c promotes bladder cancer cell migration and invasion by directly targeting RECK.

    abstract:BACKGROUND:Increasing evidence suggests that the dysregulation of certain microRNAs plays an important role in tumorigenesis and metastasis. MiR-200c exhibits a disordered expression in many tumors and presents dual roles in bladder cancer (BC). Therefore, the definite role of miR-200c in BC needs to be investigated fu...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S101067

    authors: Cheng Y,Zhang X,Li P,Yang C,Tang J,Deng X,Yang X,Tao J,Lu Q,Li P

    更新日期:2016-08-16 00:00:00

  • A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.

    abstract::We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient's tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of chemotherapy. Fortu...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S279004

    authors: Chen Y,Zhang H,Shi J,Wang T

    更新日期:2020-12-03 00:00:00

  • miR-106b-5p Inhibits IRF1/IFN-β Signaling to Promote M2 Macrophage Polarization of Glioblastoma.

    abstract:Purpose:The microRNA (miRNA) profile changes in the tumor-associated macrophages. However, the role of miR-106b-5p in the glioblastoma-associated macrophages is poorly understood. Materials and Methods:In our study, miR-106b-5p and M2 macrophage markers were detected by qRT-PCR and Western blotting in THP1 cells, with...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S238975

    authors: Shi Y,Zhang B,Zhu J,Huang W,Han B,Wang Q,Qi C,Wang M,Liu F

    更新日期:2020-07-30 00:00:00

  • Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.

    abstract::Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both early and metastatic HE...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S27733

    authors: Hamizi S,Freyer G,Bakrin N,Henin E,Mohtaram A,Le Saux O,Falandry C

    更新日期:2013-01-01 00:00:00

  • Long noncoding RNA expression profile analysis of colorectal cancer and metastatic lymph node based on microarray data.

    abstract::Long noncoding RNAs (lncRNAs) are emerging as an important part of biological progress in cancers, yet the aberrant lncRNAs implicated in colorectal cancer (CRC) with lymph node metastasis remain unknown. In this study, a total of 390 lncRNA transcripts and 508 mRNA transcripts were dysregulated in tumor tissues compa...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S102348

    authors: Yang P,Xu ZP,Chen T,He ZY

    更新日期:2016-04-26 00:00:00

  • Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma.

    abstract:Purpose:Hepatocellular carcinoma (HCC) has a high incidence in China and exploring effective ways for early diagnosis is an important method to improve the prognosis of patients with HCC. Additional studies reported that. Some kinds of microRNA (miRNA) in plasma will change accordingly during HCC progress, and this cha...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S232453

    authors: Wang S,Yang Y,Sun L,Qiao G,Song Y,Liu B

    更新日期:2020-03-09 00:00:00

  • Intravoxel incoherent motion model-based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma.

    abstract:PURPOSE:The aim of this study was to evaluate an intravoxel incoherent motion (IVIM) model-based analysis of diffusion-weighted imaging (DWI) for assessing the response of hepatocellular carcinoma (HCC) to locoregional therapy. PATIENTS AND METHODS:Respiratory-gated DWI (b=0, 50, and 800 s/mm2) was retrospectively ana...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S113909

    authors: Mürtz P,Penner AH,Pfeiffer AK,Sprinkart AM,Pieper CC,König R,Block W,Schild HH,Willinek WA,Kukuk GM

    更新日期:2016-10-19 00:00:00

  • Analysis of Differential Expression Proteins of Paclitaxel-Treated Lung Adenocarcinoma Cell A549 Using Tandem Mass Tag-Based Quantitative Proteomics.

    abstract:Background:Paclitaxel is widely used in the treatment of cancer and has a good effect in the treatment of non-small cell lung cancer. The combination of TMT proteomics and bioinformatics is used to systematically analyze the molecular mechanism of paclitaxel in the treatment of lung adenocarcinoma A549 cell, which is h...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S259895

    authors: Zheng W,Xu S

    更新日期:2020-10-13 00:00:00

  • Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery.

    abstract:BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via proteinase-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase phosphorylat...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S105368

    authors: Ammendola M,Sacco R,Sammarco G,Piardi T,Zuccalà V,Patruno R,Zullo A,Zizzo N,Nardo B,Marech I,Crovace A,Gadaleta CD,Pessaux P,Ranieri G

    更新日期:2016-07-21 00:00:00

  • Circular RNA 0001073 Attenuates Malignant Biological Behaviours in Breast Cancer Cell and Is Delivered by Nanoparticles to Inhibit Mice Tumour Growth.

    abstract:Background:Circular RNAs (circRNAs) are a special class of noncoding RNAs that are involved in gene regulation and compete with mRNA for miRNA binding sites. The roles of circRNAs in cancer, especially breast cancer (BC), are poorly understood. Materials and Methods:The expression levels of circRNA 0001073 (circ-1073)...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S248822

    authors: Yi Z,Li Y,Wu Y,Zeng B,Li H,Ren G,Wang X

    更新日期:2020-06-29 00:00:00

  • Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis.

    abstract::Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic roles of circ-SHPRH for...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S200755

    authors: Li F,Huang Q,Gong Z,Wang H,Chen J

    更新日期:2019-05-31 00:00:00

  • Ribosome Binding Protein 1 Correlates with Prognosis and Cell Proliferation in Bladder Cancer.

    abstract:Introduction:Ribosome binding protein 1 (RRBP1) is reported to be correlated with tumor formation and progression. However, the role of RRBP1 in bladder cancer is unclear. In this study, we aimed to investigate the expression of RRBP1 and its influence on cell proliferation in bladder cancer. Methods:Quantification re...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S252043

    authors: Lv SW,Shi ZG,Wang XH,Zheng PY,Li HB,Han QJ,Li ZJ

    更新日期:2020-07-07 00:00:00

  • MiR-486-5p Act as a Biomarker in Endometrial Carcinoma: Promotes Cell Proliferation, Migration, Invasion by Targeting MARK1.

    abstract:Background:miRNA expression acts as a potential biomarker in many diseases including endometrial carcinoma (EC). miR-486-5p dysregulation is observed in several tumor types, but the roles of miR-486-5p in EC are hardly ever studied. Objective:This study aimed to analyze the expression profile of miR-486-5p in tumor ti...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S246841

    authors: Zheng X,Xu K,Zhu L,Mao M,Zhang F,Cui L

    更新日期:2020-05-28 00:00:00

  • HES1 is an independent prognostic factor for acute myeloid leukemia.

    abstract::HES1 is the target of Notch signaling which is reported to affect cell differentiation and maintain the cells in G0 phase in various tissues including the hematopoietic tissue. HES1 expression appears to be an independent prognostic factor for survival in a heterogeneous group of acute myeloid leukemia (AML) patients....

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S83511

    authors: Tian C,Tang Y,Wang T,Yu Y,Wang X,Wang Y,Zhang Y

    更新日期:2015-04-22 00:00:00

  • Inhibition of microRNA-126 promotes the expression of Spred1 to inhibit angiogenesis in hepatocellular carcinoma after transcatheter arterial chemoembolization: in vivo study.

    abstract::MicroRNA-126 (miR-126) has been found to promote angiogenesis, but the underlying mechanisms are still unclear. So, we conducted this study to explore the effect of miR-126 expression on angiogenesis in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). The expression levels of miR-1...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S106513

    authors: Ji JS,Xu M,Song JJ,Zhao ZW,Chen MJ,Chen WQ,Tu JF,Yang XM

    更新日期:2016-07-19 00:00:00

  • Deleted in breast cancer 1 as a potential prognostic biomarker in human cancers: a pooled analysis of 2,254 patients.

    abstract:Background:Deleted in breast cancer 1 (DBC1) is believed to be involved in human cancers. However, it is still uncertain whether DBC1 expression can be regarded as a prognostic factor in patients with various cancers. This meta-analysis aimed to evaluate the relationship between high levels of DBC1 and prognosis in tum...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S189618

    authors: Liu G,Wu Q,Wang Y,Xiong Q,Fu F

    更新日期:2019-02-22 00:00:00

  • Sichong formula inhibits the proliferation and migration of human gastric cancer cells.

    abstract:Purpose:Traditional Chinese medicine (TCM) has gained increasing attention for the treatment of multiple chronic diseases, such as cancer. Here we aim to identify the antitumor activity of Sichong formula, a novel TCM, in human gastric cancer cells and investigate the underlying mechanisms. Methods:The AGS and MKN45 g...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S199605

    authors: Wang M,Tian Z,Zhu Y,Ding J,Li C,Zhou Y,Zhang Y

    更新日期:2019-07-16 00:00:00

  • Pancreatic cancer in young adults: changes, challenges, and solutions.

    abstract::Despite improvements in multidisciplinary treatments, survival of pancreatic cancer (PC) patients remains dismal. Studies dealing with early onset pancreatic cancer (EOPC) patients are scarce. In this review, we discuss differences between EOPC and late-onset pancreatic cancer based on findings in original papers and ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S176700

    authors: Primavesi F,Stättner S,Schlick K,Kiesslich T,Mayr C,Klieser E,Urbas R,Neureiter D

    更新日期:2019-05-06 00:00:00

  • Predictive value of single nucleotide polymorphisms in XRCC1 for radiation-induced normal tissue toxicity.

    abstract:Purpose:X-Ray Repair Cross Complementing 1 (XRCC1) functioning in the base excision repair pathway plays an important role in the repair of DNA single-strand breaks caused by ionizing radiation. The relationship between XRCC1 polymorphisms and the risk of radiation-induced side effects on normal tissues remains controv...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S156175

    authors: Zhao J,Zhi Z,Zhang M,Li Q,Li J,Wang X,Ma C

    更新日期:2018-07-06 00:00:00

  • The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis.

    abstract:PURPOSE:We validated the use of expression sequence tags (ESTs) as an effective method of screening for DNA segments that could predict urothelial cell carcinoma and for identifying ESTs with such predictive value. PATIENTS AND METHODS:From 2004 to 2009, eleven patients were enrolled in this study: six with high-grade...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S69239

    authors: Yang PS,Hsu YC,Lin YH,Hou CP,Chen CL,Chang PL,Juang HH,Tsui KH

    更新日期:2014-09-30 00:00:00

  • Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.

    abstract::Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%-3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the c...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S141053

    authors: Donato EM,Fernández-Zarzoso M,Hueso JA,de la Rubia J

    更新日期:2018-08-06 00:00:00

  • Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer.

    abstract:Purpose:Several studies have proved that single nucleotide polymorphisms (SNPs) of mismatch repair system genes are closely related to the development of colorectal cancer (CRC) by causing microsatellite instability, while effects of the SNPs of MMR system-related genes on the clinical outcomes of cytotoxic chemotherap...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S180145

    authors: Wang D,Zhang X,Zhang Y,Wu Y,Guan X,Zhu W,Wang M,Qi C,Shen B

    更新日期:2018-11-13 00:00:00

  • Helical tomotherapy provides efficacy similar to that of intensity-modulated radiation therapy with dosimetric benefits for endometrial carcinoma.

    abstract:BACKGROUND:The purpose of this study was to compare the efficacy of intensity-modulated radiotherapy (IMRT) and helical tomotherapy for endometrial cancer. METHODS:Between November 1, 2006 and November 31, 2010, 31 patients with histologically confirmed endometrial cancer were enrolled. All enrolled patients received ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S35958

    authors: Hsieh CH,Shueng PW,Hsiao SM,Wei MC,Wu WY,Sun HD,Tien HJ,Wang LY,Hsieh YP

    更新日期:2012-01-01 00:00:00